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Abstract
Background M3 muscarinic receptor antagonism has been
associated with glucose intolerance and disturbance of
insulin secretion.
Objective Our objective was to examine the risk of type 2
diabetes mellitus (T2DM) in patients using antidepressants
with and without M3 muscarinic receptor antagonism
(AD_antaM3 and AD_nonantaM3, respectively).
Methods We designed a case–control study using a phar-
macy prescription database. We selected a cohort of
patients who initiated antidepressant use between the ages
of 20 and 40 years and who did not receive any anti-dia-
betic prescriptions at baseline. Cases were defined as those
who developed T2DM [i.e., receiving oral anti-diabetic
medication, Anatomical Therapeutic Chemical (ATC) code
A10B] during the follow-up period (1994–2014), and ten
random controls were picked for each case from the cohort
of patients who did not develop T2DM.
Results A total of 530 cases with incident T2DM and 5300
controls were included. Compared with no use of antide-
pressants during the previous 2 years, recent (within the
last 6 months) exposure to AD_antaM3 was associated with
a moderately increased risk of T2DM: adjusted odds ratio
1.55 (95% confidence interval 1.18–2.02). In the stratified
analyses, this association was dose dependent ([365
defined daily doses) and significant for patients who were
in the younger age group (\45 years at the end of follow-
up), were female and had no co-morbidity. On the other
hand, recent exposure to AD_nonantaM3 was not associ-
ated with a risk for T2DM in any of our analyses.
Conclusion Our results suggest that exposure to AD_an-
taM3 was associated with the development of T2DM
among antidepressant users.
Key Points
Antagonism of M3 muscarinic receptors (antaM3)
has been related to the development of
hyperglycemia.
Recent exposure to antidepressants with antaM3
activity was associated with an increased risk for
type 2 diabetes mellitus in the adult population, but
exposure to antidepressants without antaM3 was not.
This association was dose dependent and more
pronounced in patients who were in the younger age
group (\45 years old), were female and had no co-
morbidity.
Electronic supplementary material The online version of this
article (doi:10.1007/s40263-017-0436-x) contains supplementary
material, which is available to authorized users.
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1 Introduction
Diabetes is a group of glucose metabolism disorders
leading to hyperglycemia and is classified into two main
types: type 1 diabetes mellitus (T1DM) or type 2 (T2DM).
T1DM results from autoimmune beta-cell destruction fol-
lowed by absolute insulin deficiency, whereas T2DM is
characterized by insulin resistance in peripheral tissues
(muscle, fat, and liver) and a progressive decline in pan-
creatic beta-cell function [1].
A meta-analysis found the incidence of diabetes was
significantly higher among depressed than among non-de-
pressed subjects (0.72 vs. 0.47% yearly) [2]. Several
mechanisms have been postulated for this link: eating
disorders plus sedentary lifestyle induced by depressed
mood, disturbance of the hypothalamic–pituitary–adreno-
cortical axis, disturbance of the sympathetic nervous sys-
tem, dysregulation of the immune system, and the use of
antidepressants [2, 3]. It is unclear whether antidepressants
increase the risk for diabetes or the use of antidepressants is
a proxy for depression, which can be an independent risk
factor. Recent literature also offers controversial findings
about the glycemic effect of antidepressants: while some
studies reported a significantly increased incidence of
diabetes for antidepressant users (varying from 17 to 84%)
[4–7], others found no association [3, 8–13], and one paper
even suggested that antidepressant treatment may prevent
the onset of diabetes by normalizing the abnormal physi-
ology induced by depression [14].
Inactivation of M3 muscarinic receptors by antipsy-
chotics such as clozapine and olanzapine has been associ-
ated with the development of T2DM [15, 16]. It is
suggested that these drugs decrease fasting plasma insulin
and glucose-stimulated insulin response via their antago-
nism at M3 receptors in the brain and pancreas in the short
term, whereas chronic treatment could lead to hyperinsu-
linemia, hepatic insulin resistance, and T2DM because of
compensatory upregulation of M3 receptors over time [15].
It is noteworthy that some antidepressants possess an
affinity at M3 muscarinic receptors (desipramine, imipra-
mine, amitriptyline, nortriptyline, doxepin, dosulepin,
maprotiline, and paroxetine) and may thus influence the
risk for diabetes. We hypothesized that exposure to
antidepressants with M3 antagonistic effect (AD_antaM3)
might increase the risk for T2DM.
2 Methods
2.1 Design and Setting
We designed a case–control study using the Dutch phar-
macy prescription database IADB (http://www.IADB.nl), a
population-based database that holds the prescription
records of approximately 600,000 patients in the northern
Netherlands. Each record contains basic patient informa-
tion (anonymous identifier, sex, date of birth) and medi-
cation information, including Anatomical Therapeutic
Chemical (ATC) classification code, drug dispensing date,
total amount of drugs dispensed, and dosage. Strong
commitment from patients–pharmacies in the Netherlands
means the prescription records for each patient in the
database are nearly complete, with the exception of records
of over-the-counter drugs and drugs dispensed during
hospitalization [17].
2.2 Study Population
In the study period 1994–2014, we selected a cohort of
patients aged 20–40 years who started taking antidepres-
sants (ATC codes N06A* and N06CA*, not including
Hyperici herba N06AX25). The cohort entry was defined
as the date of the first antidepressant prescription. We
included patients who received at least two antidepressant
prescriptions within the year after cohort entry. This was to
ensure persistent exposure and to prevent the possibility
that a single prescription might not have been used by the
patient.
Patients were excluded if information about the date of
birth or sex was not available, if they had less than 6
months of pharmacy data before or after the cohort entry
date, or if they had received an anti-diabetic prescription
(ATC code A10) at or before cohort entry. Because we
were interested in the risk for T2DM, patients who prob-
ably developed T1DM during follow-up (i.e., receiving
only insulin) were excluded because T1DM may have a
different etiology.
Cases were defined as patients who developed T2DM
(i.e., receiving oral anti-diabetic medication, ATC code
A10B) during the study period. The date of the first anti-
diabetic medication was defined as the index date. For each
case, we randomly selected up to ten control subjects
(matched on birth year ±2 years, cohort entry date ±1
year, and sex) from the same cohort who were still being
followed up and who had not developed diabetes. A date
that resulted in the same follow-up time in a case subject
was assigned to its respective control as the index date.
Figure 1 presents the flow diagram for the study
population.
2.3 Exposure Definition
We first identified all antidepressants used by the study
population. We classified them based on their antagonistic
activity at M3 muscarinic receptors (antaM3) using the
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lists from DrugBank [36] and the IUPHAR/BPS Guide to
Pharmacology [37] [see Table S1 in the Electronic Sup-
plementary Material (ESM) for details]. There were eight
AD_antaM3: desipramine, imipramine, amitriptyline,
nortriptyline, doxepin, dosulepin, maprotiline, and parox-
etine. The remaining antidepressants that did not antago-
nize M3 receptors (AD_nonantaM3) were clomipramine,
opipramol, trimipramine, fluoxetine, citalopram, sertra-
line, fluvoxamine, escitalopram, phenelzine, tranyl-
cypromine, moclobemide, mianserin, trazodone,
nefazodone, mirtazapine, bupropion, venlafaxine, dulox-
etine, and agomelatine.
We categorized exposure to antidepressants as ‘‘recent’’,
‘‘former’’, or ‘‘past’’ use. Recent use was defined as a
prescription that lasted into 6 months before the index date
(because a previous study [7] found this window of
antidepressant exposure to be associated with an increased
risk for diabetes); former use was defined as a prescription
that lasted into the period from 2 years to 6 months before
the index date, and past use was a prescription that ended
more than 2 years before the index date with no new pre-
scription filled until the index date. In patients recently
exposed to antidepressants, we further categorized their
exposure into subgroups: combination (AD_antaM3 and
AD_nonantaM3), AD_antaM3 only, and AD_nonantaM3
only.
2.4 Covariates
Co-medications were included as study covariates and
comprised benzodiazepines and drugs that have been
documented to disturb glucose homeostasis: beta-blockers,
thiazide diuretics, systemic corticosteroids, calcineurin
inhibitors, and antipsychotics [18]. To be considered co-
medications, these drugs had to have been used in the
previous 6 months before the index date. Although the
hyperglycemic effect of benzodiazepines is unknown, we
considered them co-medications because they are primarily
prescribed for psychosocial complaints that have been
associated with diabetes [3]. Given that (1) many
antipsychotics are well-known for their antaM3 [15], (2)
the US FDA has issued a special warning about the dia-
betogenic risk of antipsychotic agents, and (3) higher
percentages of cases were exposed to antipsychotics than
were controls (Table 1), this could influence our findings if
antaM3 is associated with the risk for T2DM. We therefore
excluded patients with a concurrent use of antipsychotics in
subsequent analyses (see Sect. 2.5).
2.5 Statistical Analysis
We used SPSS 22.0 for Windows (IBM Corp., Armonk,
NY, USA) to perform the analyses.
26,475 patients received at least two 
antidepressant prescriptions within the year 
after cohort entry
During follow-up:
- 530 patients developed type 2 diabetes 
mellitus (cases)
- 25,945 patients did not develop diabetes
(potential controls)
Randomly matched (1:10) on birth year, 
cohort entry, sex and follow-up range:
- 530 cases
- 5,300 controls
34,380 patients initiated antidepressants
between 20 and 40 years of age (having ≥ 6 
months of data before and ≥ 6 months of data 
after cohort entry and having no diabetes at 
cohort entry)
7,905 were excluded:
- 115 developed type 1 diabetes mellitus
- 7,790 received only one antidepressant 
prescription within a year after cohort entry
Fig. 1 Flow diagram of the study population
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The following descriptive statistics were used to
describe the study population: age at index date, sex, fol-
low-up time, comorbidities, and co-medications. We con-
sidered cardiovascular diseases and dyslipidemia as
comorbidities and used the drugs dispensed in the year
preceding their index date as a proxy for these diseases
[19]. Cardiovascular comorbidities were defined as patients
exposed to the following drugs: cardiac therapy ATC code
C01*, antihypertensives C02*, diuretics C03*, beta
blockers C07*, calcium channel blockers C08*, agents
acting on the rennin–angiotensin systems C09*, and
antithrombotic agents B01*. Dyslipidemia comorbidities
were defined as patients exposed to lipid-modifying agents
(C10*). A p value \0.05 was considered statistically
significant.
Past use was considered the reference category in all our
analyses. To account for the inter-dependency between a
case and its matched controls, a conditional logistic
regression was used to calculate the odds ratios (ORs) and
95% confidence intervals (CIs) of developing T2DM in
patients with former use and recent use of antidepressants
(including the antidepressant combination, AD_antaM3
only, and AD_nonantaM3 only). We also calculated the
risk for T2DM in the presence and absence of antipsychotic
co-medication.
Since the persistency of the effect of AD_antaM3 (if
any) is unknown, we undertook sensitivity analyses on
other time windows of recent use (i.e., previous 3 months,
previous 1 month, and currently being treated) to examine
whether the results changed notably.
We also performed stratified analyses to examine whe-
ther the association with T2DM was modified by the
patients’ characteristics, including age at index date, sex,
and comorbidities. Only a few patients were exposed to the
antidepressant combination (both AD_antaM3 and
AD_nonantaM3), so this subgroup was not included in the
stratified analyses.
To investigate the dose–response relationship between
antidepressant use and new-onset T2DM, we calculated the
cumulative defined daily dose (DDD; defined by the World
Health Organization as ‘‘the assumed average maintenance
dose per day for a drug used for its main indication in
adults’’ [38]) that recent users had been prescribed from
their starting point to the index date. If patients had used
antidepressants (either AD_antaM3 or AD_nonantaM3)
continuously since cohort entry, the starting point would be
their cohort entry date. If patients had stopped using
antidepressants for more than 6 months (discontinuation)
and then restarted, the starting point would be the date of
first antidepressant prescription after the discontinuation
period. We used DDD as a dose standard unit for various
antidepressants. The cumulative DDDs were calculated as
the number of DDDs per day multiplied by the number of
days (duration) the patients had been continuously using
the drugs. We chose the cut-off values of B180 DDDs,
181–365 DDDs, and [365 DDDs to examine the dose–
response relationship of the antidepressant subgroups.
We adjusted for covariates in the regression models. To
limit statistical instability, we did not calculate ORs if there
were fewer than five cases or controls per exposure category.
3 Results
The study population included 530 cases with new-onset
diabetes and 5300 matching controls. Their characteristics
are shown in Table 1. The mean follow-up period was 7.8
[standard deviation (SD) 4.7] years.
Our matching criteria ensured characteristics such as
age, sex, and follow-up time were similar for cases and
controls (Table 1). The majority of patients developed
T2DM before the age of 45 years. At the index date, the
oldest patients were aged 56.7 and 58.4 years in the case
and control groups, respectively. The diabetic cases were
more likely to have a comorbidity (i.e., cardiovascular
diseases and/or dyslipidemia) preceding the occurrence of
T2DM. They were also more likely to have received
medications associated with psychosocial problems (i.e.,
benzodiazepines) or with hyperglycemia (i.e., beta block-
ers, thiazide diuretics, systemic corticosteroids, or
antipsychotics). Only a few patients received calcineurin
inhibitors (and exposure rates were similar in the case and
control groups), so we did not adjust for this covariate in
further regression models.
When we considered antidepressant users (Table 1),
patients with past use of antidepressants were significantly
older than other users at the index date. However, comor-
bidities were more prevalent among recent users. For the
antidepressant subgroups, patients with past or recent use
of AD_nonantaM3 had a significantly longer follow-up
time than recent users of AD_antaM3 (9.1 and 7.7 vs. 6.7
years, respectively). Antipsychotics were more frequently
used by patients with AD_nonantaM3 and by patients with
the antidepressant combination.
Table 2 shows that the majority of exposed cases were
from the past and recent use categories. Incident T2DM
was associated with recent use of antidepressants but not
with former use in the multivariate-adjusted regression
model. Results for the four time windows (i.e., previous 6
months, previous 3 months, previous 1 month, and cur-
rently being treated) were similar. All showed a signifi-
cantly increased albeit moderate risk of T2DM in recent
AD_antaM3 users (OR approximately 1.50), but not in
AD_nonantaM3 users. Therefore, it was reasonable to
select the window of previous 6 months for further
analyses.




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































488 Y. Tran et al.
It is worth noting that, in Table 2, ORs were reduced in
patients with no concurrent use of antipsychotics; therefore,
patient use of antipsychotics might influence our findings. To
examine the role of AD_antaM3 and AD_nonantaM3 in
T2DM development, we further excluded patients with
antipsychotic comedication (86 cases and 320 controls) in
the subsequent analyses.
On examining patients’ records for characteristics that
predicted the risk for T2DM (Fig. 2), we found an elevated
risk of T2DM with AD_antaM3 exposure in patients who
were aged\45 years at the index date (OR 1.70; 95% CI
1.19–2.42), were female (OR 1.71; 95% CI 1.20–2.44), and
had no prevalent comorbidity (OR 1.74; 95% CI
1.16–2.63). In contrast, exposure to AD_nonantaM3 was
not associated with a risk for T2DM in any strata.
Table 3 demonstrates a relationship between the dosing
regimens of AD_antaM3 and the development of T2DM. We
found that the increased use of AD_antaM3 was significantly
associated with T2DM ([365 DDDs: OR 1.57; 95% CI
1.12–2.19), whereas lower dosing regimens of AD_antaM3
and any use of AD_nonantaM3 showed no association.
4 Discussion
We examined the risk of T2DM in patients exposed to
antidepressants from a mechanism-based point of view.
Antidepressants were grouped according to their antaM3
effect. The results showed that recent exposure to
AD_antaM3 significantly increased the risk of new-onset
T2DM by 50% but former use of antidepressants had no
effect. However, the increased risk with AD_antaM3 had a
moderate magnitude and was associated with a higher
dosing regimen ([365 DDDs). On the other hand, recent
exposure to AD_nonantaM3 was not associated with
T2DM development at any dose.
The literature suggests an increased incidence of T2DM
in people aged [45 years [20], which may be due to a
weakening of the antioxidant defense system with aging
[21]. While previous studies about the risk of T2DM
among antidepressant users [3–13, 22] focused on the adult
population and had no upper age limit, our study selected a
fairly young cohort who initiated antidepressants between
the age of 20–40 years and, by the end of the follow-up,
developed T2DM before the age of 60 years. In agreement
with previous studies that found a positive association
between antidepressants and T2DM in the younger age
group (\45 years) [5] and in females [9], our stratification
analyses revealed similar findings for AD_antaM3 users but
not for AD_nonantaM3 users. Although we and other
authors [5, 7] noted a higher prevalence of comorbidities
(cardiovascular diseases and dyslipidemia) among diabetic
cases, their relationship with T2DM is still unclear. It has
been suggested that these comorbidities may share a
common genetic pathway with T2DM [23] or result from
Fig. 2 Risk of type 2 diabetes in patients with ‘recent use’ of
antidepressants (excluding patients with concurrent use of antipsy-
chotics), stratified by patients’ characteristics. AD_antaM3
Antidepressants that antagonize M3 muscarinic receptors; AD_nonan-
taM3 Antidepressants that do not antagonize M3 muscarinic receptors;
OR Odds ratio; CI Confidence interval
Antidepressants Antagonizing M3 Muscarinic Receptors and Incident T2DM 489
the use of antidepressants [24]. If this is true, patients with
these comorbidities might have an increased risk for
T2DM, and this could influence our findings. When we
examined the group of patients without comorbidities, the
association with T2DM remained for AD_antaM3 users but
not for AD_nonantaM3 users. This strengthens our
hypothesis that AD_antaM3 is associated with a risk for
T2DM.
When the sensitivity analyses were performed for dif-
ferent time windows of exposure, the effect magnitude did
not change. We therefore believe that our choice of a
6-month recent window was justified. Our reference group
included patients with a past use of antidepressants who
had a longer follow-up than patients recently treated with
AD_antaM3. If follow-up time had any influence on the
incidence of T2DM, it would lead to a decrease (rather than
an increase) in the effect magnitude of AD_antaM3.
Therefore, the association between AD_antaM3 and T2DM
remains valid.
Although the risk of T2DM has been widely studied in
antidepressant users [3–13, 22], only a few publications
[4, 5, 7, 9] examined the types of antidepressants, and only
Andersohn et al. [7] specified this risk for individual
antidepressants. However, Andersohn et al. [7] did not take
the antaM3 mechanism into account and thus did not
exclude patients with antipsychotic co-medication as we
did. In addition, we applied stricter inclusion criteria for the
study population (i.e., ages 20–40 years at cohort entry date
and receiving at least two prescriptions within a year after
cohort entry) than did Andersohn et al. [7]. To examine the
risk of T2DM in individual antidepressants, we only con-
sidered the exposure to a single antidepressant and thus
additionally excluded patients who received two or more
different antidepressants within the previous 6 months
(except for those receiving amitriptyline and/or nortripty-
line and those receiving citalopram and/or escitalopram
because of the relation between these compounds, i.e.,
nortriptyline is the metabolite of amitriptyline and esci-
talopram is the S-enantiomer of citalopram). Adopting such
criteria meant we only had a limited number of patients left
for our analysis (Table S2 in the ESM). Andersohn et al.
[7] found a borderline increased risk with amitriptyline,
fluvoxamine, and paroxetine and the highest risk with
venlafaxine. Our study also found a modestly increased
risk with amitriptyline and/or nortriptyline. In contrast,
venlafaxine and fluvoxamine, which were classified as
AD_nonantaM3, had lower exposure rates in cases than in
controls. In agreement with the results of Andersohn at al.
[7], we found the exposure rate to paroxetine was 18%
higher in cases than in controls. However, this difference
Table 3 Risk of type 2 diabetes mellitus in patients with recent use of antidepressants and with no concurrent use of antipsychotics, stratified by
cumulative defined daily doses













Past usec 193 (43.5) 2474 (49.7) 1 193 (44.6) 2474 (50.2) 1
Recent users of AD_antaM3
d
B180 DDDs 31 (7.0) 247 (5.0) 1.55 (0.91–2.64) 27 (6.2) 217 (4.4) 1.49 (0.84–2.64)
180–365 DDDs 10 (2.3) 99 (2.0) 0.93 (0.42–2.06) 9 (2.1) 94 (1.9) 0.90 (0.39–2.07)
[365 DDDs 71 (16.0) 496 (10.0) 1.67 (1.21–2.30) 65 (15.0) 484 (9.8) 1.57 (1.12–2.19)
Recent users of AD_nonantaM3
d
B180 DDDs 25 (5.6) 217 (4.4) 1.51 (0.87–2.62) 22 (5.1) 187 (3.8) 1.61 (0.90–2.86)
180–365 DDDs 6 (1.4) 131 (2.6) 0.56 (0.21–1.52) 6 (1.4) 123 (2.5) 0.55 (0.20–1.55)
[365 DDDs 60 (13.5) 642 (12.9) 1.15 (0.82–1.59) 52 (12.0) 633 (12.8) 1.05 (0.74–1.49)
Data are presented as n (%) unless otherwise indicated
ORs were adjusted for the following covariates: use of benzodiazepines, beta blockers, thiazide diuretics, and systemic corticosteroids within the
previous 6 months
AD_antaM3 antidepressants that antagonize M3 muscarinic receptors, AD_nonantaM3 antidepressants that do not antagonize M3 muscarinic
receptors, CI confidence interval, combination both AD_antaM3 and AD_nonantaM3, DDD defined daily dose, OR odds ratio
a Including patients who recently received the combination of AD_antaM3 and AD_nonantaM3. Only the number of DDDs of AD_antaM3 was
summed in the category of AD_antaM3 and vice versa
b Excluding patients who recently received the combination of AD_antaM3 and AD_nonantaM3
c Reference category. Past use was defined as a patient who received a prescription of antidepressants (with or without M3 muscarinic receptor
antagonism) that ended more than 2 years before the index date and no new prescription was filled until the index date
d There were 11 cases and 47 controls recently exposed to the combination of AD_antaM3 and AD_nonantaM3
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did not reach significance in our study. Possible explana-
tions include the limited number of patients and the very
low affinity towards M3 muscarinic receptors of paroxetine
compared with other AD_antaM3 (amitriptyline had the
highest affinity) [25]. Increasing exposure to paroxetine
(i.e., by combining with pravastatin) has been shown to
increase the risk for T2DM [26–28]. However, we could
not examine the paroxetine–pravastatin combination
because it was used by only three cases. Interestingly,
paroxetine is a unique antidepressant with an antioxidant
property that, paradoxically, mitigates the hyperglycemic
adverse effect [29].
We examined antaM3 as the antidepressant mechanism
that increased the risk for T2DM. Other mechanisms are
also proposed in the literature. For example, because
serotonin is involved in glucose homeostasis, and most
antidepressants (except for agomelatine and bupropion) act
by increasing the neurotransmission of serotonin [13–15],
use of antidepressants may alter the regulation of glucose
and subsequently increase the risk for T2DM [16]. How-
ever, an examination of AD_nonantaM3 with serotonin
effect (excluding agomelatine and bupropion) found no
association with incident T2DM (Table S3 in the ESM).
Another mechanism is antagonism of the 5-HT2C recep-
tors, which can lead to weight gain and subsequent insulin
resistance [16], although this effect is expected to be minor
[17]. In addition, activities of 5-HT2A receptors (either
agonism or antagonism) have been involved in insulin
secretion and insulin resistance, but experimental studies
[30–32] reported inconsistent findings. No antidepressants
with 5-HT2A activation effects were used by our study
population. Among antidepressants with 5-HT2A/5-HT2C
antagonism, four were classified in the AD_antaM3 sub-
group (imipramine, amitriptyline, nortriptyline, and dox-
epin) and five in the AD_nonantaM3 subgroup
(clomipramine, amoxapine, mianserin, nefazodone, mir-
tazapine). However, we found no increased risk of T2DM
in patients using AD_nonantaM3 with 5-HT2A/5-HT2C
antagonism (Table S2 in the ESM).
An alternative explanation for the association between
AD_antaM3 and T2DM is the presence and/or severity of
depression, which is also a risk factor for T2DM [8, 12].
However, confounding by indication was unlikely in this
study, based on findings from the other exposure subgroup,
AD_nonantaM3. On the one hand, recent use of
AD_nonantaM3 suggested the prevalence of depressive
symptoms. On the other hand, given Table 1, AD_nonan-
taM3 users had a significantly longer follow-up time than
AD_antaM3 users (7.7 vs. 6.7 years, post hoc analysis p\
0.001). This implies that AD_nonantaM3 did not relate to
initial treatment of depression in our study population and
that users of AD_nonantaM3 were not likely to have a
shorter duration of depression or less severe symptoms than
AD_antaM3 users. Since recent use of AD_antaM3
increased the risk for T2DM but recent use of
AD_nonantaM3 did not, none of our analyses suggest the
association of AD_antaM3 with T2DM was affected by the
presence and/or severity of depression.
We used a large prescription database representative of
the Dutch population with proven high accuracy and the
possibility of tracking patients over time even when
patients receive their medications from different pharma-
cies [17, 33]. Both antidepressant exposure and new-onset
T2DM were recorded prospectively, so results were not
affected by recall bias. Therefore, this database is suit-
able for our current study design, which requires a large
sample size with matching conditions and a long follow-up
time.
However, our study does have some limitations. First, we
do not know whether patients actually took the drugs. If
patients had poor compliance due to their mental status (e.g.,
being depressed), this could lead to an overestimation of
exposure. However, if compliance was poor, it would be
expected to have the same effect direction in both the case
and the control groups and in the subgroups of antidepressant
users. Second, since the definition of T2DM (the outcome)
was based on the use of oral anti-diabetic medications,
potential T2DM cases might have been missed if they were
undiagnosed, were managed solely with lifestyle therapy
(diet and exercise), or were initially treated with insulin
because of impaired renal function. To account for the first
and second instances, we conducted an additional sensitivity
analysis comparing patients who used AD_antaM3 or
AD_nonantaM3 continuously for more than 1 year (without
discontinuation) with past users. The 1-year window of
continuous use allowed more exposure time for a diabetic
case to be detected and for detection of patients initially
treated with lifestyle therapy. This could improve detection
of lifestyle therapy because, for most patients with T2DM,
this treatment will be insufficient within the first year and
then pharmacologic therapy should be started [34]. In this
additional analysis, the risk for T2DM remained signifi-
cantly increased for AD_antaM3 users but not for
AD_nonantaM3 users [adjusted OR 1.44 (95% CI 1.04–1.99)
vs. 0.97 (95% CI 0.69–1.37)]. In the third instance, our study
selected a rather young cohort (as previously mentioned),
and therefore a severe reduction in kidney function was
unlikely (it should be noted that metformin is the first-line
therapy for T2DM and is contraindicated in markedly
impaired renal function, i.e., estimated glomerular filtration
rate\30 ml/min [35]). Although the glycated hemoglobin
(HbA1c) values of patients were not available, given the
above approach we believe the number of undetected T2DM
cases (if any) was not particularly substantial. Finally, the
database did not record patient lifestyle factors such as
smoking, body mass index, and obesity, which may be
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related to insulin resistance. This should not lessen our
findings because (1) our study was designed with a random
matching method, in which cases and controls originated
from one large cohort (26,475 antidepressant users), which
would smooth the problem of any unequally distributed risk
factors; (2) we used cardiovascular diseases and dyslipi-
demia as a proxy for obesity, and still found an effect of
AD_antaM3 in the stratification analyses; (3) it is possible
that depressed patients might have eating disorders and
sedentary lifestyles that could result in overweight/obesity
and enhance their susceptibility to T2DM; however, this
effect would be expected to have the same impact in both the
case and the control groups and in the subgroups of antide-
pressant users; and, finally, (4) our findings about AD_an-
taM3 were strengthened by detecting a dose–response
relationship with the increased risk of T2DM at[365 DDDs.
5 Conclusions
We found exposure to AD_antaM3 to be associated with a
moderately increased risk of new-onset T2DM. This
increased risk was seen in patients who aged\45 years at
the index date, were female, had no comorbidities, and
were exposed to a higher dosing regimen ([365 DDDs). In
contrast, the use of AD_nonantaM3 was not associated with
T2DM in any analyses. Based on the results from the two
treatment subgroups (AD_antaM3 vs. AD_nonantaM3), we
suggest that antagonism of M3 muscarinic receptors has an
important role in the development of T2DM among users
of antidepressants. Further large population-based studies
to confirm our findings are warranted.
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